The DOI matches its Crossref record; 118 of the 118 references it cites were found in a registry or an index.
Virus‐like particles: Next‐generation nanoparticles for targeted therapeutic delivery
Open accessAbstract
Most drug therapies distribute the agents throughout the entire body, even though the drugs are typically only needed at specific tissues. This often limits dosage and causes discomfort and harmful side‐effects. Significant research has examined nanoparticles (NPs) for use as targeted delivery vehicles for therapeutic cargo, however, major clinical success has been limited. Current work focuses mainly on liposomal and polymer‐based NPs, but emerging research is exploring the engineering of viral capsids as noninfectious protein‐based NPs—termed virus‐like particles (VLPs). This review covers the research that has been performed thus far and outlines the potential for these VLPs to become highly effective delivery vehicles that overcome the many challenges encountered for targeted delivery of therapeutic cargo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002 · cited 1×
“As mentioned previously, targeted drug delivery by NPs must overcome multiple challenges (Table 1).(31) The ability to overcome these challenges must either be intrinsic or be imparted as the VLPs are prepared by: (a) loading the cargo inside the NP, and (b) functionalizing the NP to deliver its cargo primarily to the…”
BackgroundPushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier
Makadia, H. K., & Siegel, S. J. (2011) · Polymers · doi:10.3390/polym3031377 · Cited by 4,816
Design of polymeric nanoparticles for biomedical delivery applications
Elsabahy, M., & Wooley, K. L. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15327k · Cited by 1,717
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,676
New developments in liposomal drug delivery
Pattni, B. S., Chupin, V. V., & Torchilin, V. P. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00046 · Cited by 1,600
Nanoparticle Delivery of Cancer Drugs
Wang, A. Z., Langer, R., & Farokhzad, O. C. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-040210-162544 · Cited by 1,561
Particle shape: A new design parameter for micro- and nanoscale drug delivery carriers
Champion, J. A., Katare, Y. K., & Mitragotri, S. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.03.022 · Cited by 1,206
Gene therapy clinical trials worldwide to 2012 – an update
Ginn, S. L., Alexander, I. E., Edelstein, M. L., Abedi, M. R., & Wixon, J. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2698 · Cited by 1,159
Cited by
Strategies for delivering therapeutics across the blood–brain barrier
Terstappen, G. C., Meyer, A. H., Bell, R. D., & Zhang, W. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00139-y · Cited by 1,138
Major findings and recent advances in virus–like particle (VLP)-based vaccines
Mohsen, M. O., Zha, L., Cabral-Miranda, G., & Bachmann, M. F. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.014 · Cited by 555
Brief update on endocytosis of nanomedicines
Patel, S., Kim, J., Herrera, M., Mukherjee, A., Kabanov, A. V., & Sahay, G. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.08.004 · Cited by 400
Photoluminescent Nanoparticles for Chemical and Biological Analysis and Imaging
Algar, W. R., Massey, M., Rees, K., Higgins, R., Krause, K. D., Darwish, G. H., Peveler, W. J., Xiao, Z., Tsai, H.-Y., Gupta, R., et al. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01176 · Cited by 356
Protein Nanoparticles: Promising Platforms for Drug Delivery Applications
Jain, A., Singh, S. K., Arya, S. K., Kundu, S. C., & Kapoor, S. (2018) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b01098 · Cited by 308
Use of magnetic fields and nanoparticles to trigger drug release and improve tumor targeting
Liu, J. F., Jang, B., Issadore, D., & Tsourkas, A. (2019) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1571 · Cited by 265
Next‐Generation Vaccines: Nanoparticle‐Mediated DNA and mRNA Delivery
Ho, W., Gao, M., Li, F., Li, Z., Zhang, X., & Xu, X. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202001812 · Cited by 261
Controlling timing and location in vaccines
Irvine, D. J., Aung, A., & Silva, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.019 · Cited by 254
Phage display as a tool for vaccine and immunotherapy development
Hess, K. L., & Jewell, C. M. (2020) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10142 · Cited by 134
(2023) · doi:10.3390/vaccines11050919 · Cited by 50
Metadata
- Authors
- Rohovie, M. J., Nagasawa, M., & Swartz, J. R.
- Venue
- Bioengineering & Translational Medicine
- Publisher
- Wiley
- Published
- 2017-01-19
- Volume
- 2
- Issue
- 1
- Pages
- 43-57
- ISSN
- 2380-6761 (ISSN-L)
- OpenAlex
- W2562690513
- Cited by
- 340
- References
- 118
- FWCI
- 10.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.